Efficacy and safety of nintedanib in patients with systemic sclerosis-associated interstitial lung disease treated with mycophenolate: a subgroup analysis of the SENSCIS trial

Nintedanib for Systemic Sclerosis–Associated Interstitial Lung Disease

(2019) Oliver Distler et al.   NEW ENGLAND JOURNAL OF MEDICINE

Tracking Impact of Interstitial Lung Disease in Systemic Sclerosis in a Complete Nationwide Cohort

(2019) Anna-Maria Hoffmann-Vold et al.   AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE

Effect of mycophenolate mofetil (MMF) on systemic sclerosis-related interstitial lung disease with mildly impaired lung function: a double-blind, placebo-controlled, randomized trial

(2019) G. S. R. S. N. K. Naidu et al.   RHEUMATOLOGY INTERNATIONAL

Reliability and Minimal Clinically Important Differences of FVC. Results from the Scleroderma Lung Studies (SLS-I and SLS-II)

(2018) Suzanne Kafaja et al.   AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE

Short-term progression of interstitial lung disease in systemic sclerosis predicts long-term survival in two independent clinical trial cohorts

(2018) Elizabeth R Volkmann et al.   ANNALS OF THE RHEUMATIC DISEASES

Short-Term Pulmonary Function Trends Are Predictive of Mortality in Interstitial Lung Disease Associated With Systemic Sclerosis

(2017) Nicole S. Goh et al.   Arthritis & Rheumatology

Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial

(2016) Donald P Tashkin et al.   Lancet Respiratory Medicine

Nintedanib inhibits fibroblast activation and ameliorates fibrosis in preclinical models of systemic sclerosis

(2015) Jingang Huang et al.   ANNALS OF THE RHEUMATIC DISEASES

Mode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis

(2015) Lutz Wollin et al.   EUROPEAN RESPIRATORY JOURNAL

Safety and Effectiveness of Mycophenolate in Systemic Sclerosis. A Systematic Review

(2015) Mohammed A. Omair et al.   PLoS One

Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis

(2014) Luca Richeldi et al.   NEW ENGLAND JOURNAL OF MEDICINE

2013 classification criteria for systemic sclerosis: an American college of rheumatology/European league against rheumatism collaborative initiative

(2013) Frank van den Hoogen et al.   ANNALS OF THE RHEUMATIC DISEASES

Multi-ethnic reference values for spirometry for the 3–95-yr age range: the global lung function 2012 equations

(2012) Philip H. Quanjer et al.   EUROPEAN RESPIRATORY JOURNAL